Literature DB >> 23489378

Beyond DNA repair, the immunological role of PARP-1 and its siblings.

Maria Manuela Rosado1, Elisabetta Bennici, Flavia Novelli, Claudio Pioli.   

Abstract

ADP-ribosylation is the addition of one or more (up to some hundreds) ADP-ribose moieties to acceptor proteins. There are two major families of enzymes that catalyse this reaction: extracellular ADP-ribosyl-transferases (ARTs), which are bound to the cell membrane by a glycosylphosphatidylinositol anchor or are secreted, and poly(ADP-ribose)-polymerases (PARPs), which are present in the cell nucleus and/or cytoplasm. Recent findings revealed a wide immunological role for ADP-ribosylating enzymes. ARTs, by sensing extracellular NAD concentration, can act as danger detectors. PARP-1, the prototypical representative of the PARP family, known to protect cells from genomic instability, is involved in the development of inflammatory responses and several forms of cell death. PARP-1 also plays a role in adaptive immunity by modulating the ability of dendritic cells to stimulate T cells or by directly affecting the differentiation and functions of T and B cells. Both PARP-1 and PARP-14 (CoaSt6) knockout mice were described to display reduced T helper type 2 cell differentiation and allergic responses. Our recent findings showed that PARP-1 is involved in the differentiation of Foxp3+ regulatory T (Treg) cells, suggesting a role for PARP-1 in tolerance induction. Also ARTs regulate Treg cell homeostasis by promoting Treg cell apoptosis during inflammatory responses. PARP inhibitors ameliorate immune-mediated diseases in several experimental models, including rheumatoid arthritis, colitis, experimental autoimmune encephalomyelitis and allergy. Together these findings show that ADP-ribosylating enzymes, in particular PARP-1, play a pivotal role in the regulation of immune responses and may represent a good target for new therapeutic approaches in immune-mediated diseases.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  autoimmunity; immunotherapeutics; inflammation

Mesh:

Substances:

Year:  2013        PMID: 23489378      PMCID: PMC3719060          DOI: 10.1111/imm.12099

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  105 in total

Review 1.  Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation.

Authors:  W Lee Kraus
Journal:  Curr Opin Cell Biol       Date:  2008-04-29       Impact factor: 8.382

2.  PARP-14, a member of the B aggressive lymphoma family, transduces survival signals in primary B cells.

Authors:  Sung Hoon Cho; Shreevrat Goenka; Tiina Henttinen; Prathyusha Gudapati; Arja Reinikainen; Christine M Eischen; Riitta Lahesmaa; Mark Boothby
Journal:  Blood       Date:  2009-01-15       Impact factor: 22.113

3.  Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3.

Authors:  Lari Lehtiö; Ann-Sofie Jemth; Ruairi Collins; Olga Loseva; Andreas Johansson; Natalia Markova; Martin Hammarström; Alex Flores; Lovisa Holmberg-Schiavone; Johan Weigelt; Thomas Helleday; Herwig Schüler; Tobias Karlberg
Journal:  J Med Chem       Date:  2009-05-14       Impact factor: 7.446

4.  Glycosylphosphatidylinositol-anchored arginine-specific ADP-ribosyltransferase7.1 (Art7.1) on chicken B cells: the possible role of Art7 in B cell receptor signalling and proliferation.

Authors:  Masaharu Terashima; Mai Takahashi; Makoto Shimoyama; Yoshinori Tanigawa; Takeshi Urano; Mikako Tsuchiya
Journal:  Mol Cell Biochem       Date:  2008-08-12       Impact factor: 3.396

5.  A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial.

Authors:  David A Morrow; Chaim M Brickman; Sabina A Murphy; Kenneth Baran; Ricardo Krakover; Harold Dauerman; Sujatha Kumar; Natanya Slomowitz; Laura Grip; Carolyn H McCabe; Andrew L Salzman
Journal:  J Thromb Thrombolysis       Date:  2008-06-06       Impact factor: 2.300

6.  Poly (ADP-ribose) polymerases (PARPs) 1-3 regulate astrocyte activation.

Authors:  Nirmal K Phulwani; Tammy Kielian
Journal:  J Neurochem       Date:  2008-04-10       Impact factor: 5.372

7.  The Val762Ala polymorphism in the poly(ADP-ribose) polymerase-1 gene is not associated with susceptibility in Turkish rheumatoid arthritis patients.

Authors:  Ilhan Onaran; Gülçin Tezcan; Levent Ozgönenel; Esra Cetin; Alper Tunga Ozdemir; Gönül Kanigür-Sultuybek
Journal:  Rheumatol Int       Date:  2008-11-22       Impact factor: 2.631

8.  Parp1 facilitates alternative NHEJ, whereas Parp2 suppresses IgH/c-myc translocations during immunoglobulin class switch recombination.

Authors:  Isabelle Robert; Françoise Dantzer; Bernardo Reina-San-Martin
Journal:  J Exp Med       Date:  2009-04-13       Impact factor: 14.307

Review 9.  Poly (ADP-ribose) glycohydrolase (PARG) and its therapeutic potential.

Authors:  Wookee Min; Zhao-Qi Wang
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01

Review 10.  Parthanatos, a messenger of death.

Authors:  Karen Kate David; Shaida Ahmad Andrabi; Ted Murray Dawson; Valina Lynn Dawson
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01
View more
  81 in total

1.  Transcriptional Reprogramming and Resistance to Colonic Mucosal Injury in Poly(ADP-ribose) Polymerase 1 (PARP1)-deficient Mice.

Authors:  Claire B Larmonier; Kareem W Shehab; Daniel Laubitz; Deepa R Jamwal; Fayez K Ghishan; Pawel R Kiela
Journal:  J Biol Chem       Date:  2016-02-24       Impact factor: 5.157

2.  Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1.

Authors:  Ronit Mazor; Emily King; Ira Pastan
Journal:  Cell Immunol       Date:  2018-08-28       Impact factor: 4.868

Review 3.  The natural history of ADP-ribosyltransferases and the ADP-ribosylation system.

Authors:  L Aravind; Dapeng Zhang; Robson F de Souza; Swadha Anand; Lakshminarayan M Iyer
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

4.  Interferon-stimulated poly(ADP-Ribose) polymerases are potent inhibitors of cellular translation and virus replication.

Authors:  Svetlana Atasheva; Elena I Frolova; Ilya Frolov
Journal:  J Virol       Date:  2013-12-11       Impact factor: 5.103

5.  NAD metabolism in aging and cancer.

Authors:  John Wr Kincaid; Nathan A Berger
Journal:  Exp Biol Med (Maywood)       Date:  2020-06-05

6.  Contribution of poly(ADP-ribose)polymerase-1 activation and apoptosis in trichloroethene-mediated autoimmunity.

Authors:  Gangduo Wang; Huaxian Ma; Jianling Wang; M Firoze Khan
Journal:  Toxicol Appl Pharmacol       Date:  2018-10-10       Impact factor: 4.219

7.  Targeting DNA Repair to Drive Immune Responses: It's Time to Reconsider the Strategy for Clinical Translation.

Authors:  Nobuyuki Takahashi; Ira Surolia; Anish Thomas
Journal:  Clin Cancer Res       Date:  2020-02-17       Impact factor: 12.531

8.  IL10 Promoter Polymorphisms are Associated with Rheumatic Heart Disease in Saudi Arabian Patients.

Authors:  Atiyeh M Abdallah; Aisha Alnuzha; Abdulhadi H Al-Mazroea; Amr E Eldardear; Ala Y AlSamman; Yousef Almohammadi; Khalid M Al-Harbi
Journal:  Pediatr Cardiol       Date:  2015-08-09       Impact factor: 1.655

9.  Correlation of increased PARP14 and CCL26 expression in biopsies from children with eosinophilic esophagitis.

Authors:  Purna Krishnamurthy; Joseph D Sherrill; Kalyan Parashette; Shreevrat Goenka; Marc E Rothenberg; Sandeep Gupta; Mark H Kaplan
Journal:  J Allergy Clin Immunol       Date:  2013-11-12       Impact factor: 10.793

10.  Poly-ADP-ribosyl polymerase-14 promotes T helper 17 and follicular T helper development.

Authors:  Purvi Mehrotra; Purna Krishnamurthy; Jie Sun; Shreevrat Goenka; Mark H Kaplan
Journal:  Immunology       Date:  2015-09-28       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.